These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23875690)

  • 1. Boronic esters in asymmetric synthesis.
    Matteson DS
    J Org Chem; 2013 Oct; 78(20):10009-23. PubMed ID: 23875690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric copper-catalyzed synthesis of alpha-amino boronate esters from N-tert-butanesulfinyl aldimines.
    Beenen MA; An C; Ellman JA
    J Am Chem Soc; 2008 Jun; 130(22):6910-1. PubMed ID: 18461938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Captivating bortezomib: an active but still mysterious drug.
    Di Raimondo F; Conticello C
    Leuk Res; 2010 Apr; 34(4):411-2. PubMed ID: 19819547
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of bortezomib in the treatment of lymphoma.
    Barr P; Fisher R; Friedberg J
    Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies.
    Fisher RI
    J Clin Oncol; 2005 Feb; 23(4):657-8. PubMed ID: 15613690
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib in mantle cell lymphoma.
    Suh KS; Goy A
    Future Oncol; 2008 Apr; 4(2):149-68. PubMed ID: 18407730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bortezomib].
    Simons S; Scheulen ME; Jaehde U
    Dtsch Med Wochenschr; 2006 Feb; 131(5):214-8. PubMed ID: 16440269
    [No Abstract]   [Full Text] [Related]  

  • 8. A copper-catalyzed Petasis reaction for the synthesis of tertiary amines and amino esters.
    Frauenlob R; García C; Bradshaw GA; Burke HM; Bergin E
    J Org Chem; 2012 May; 77(9):4445-9. PubMed ID: 22494355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib for previously untreated multiple myeloma.
    Delforge M
    Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Classification and synthesis of ubiquitin-proteasome inhibitor].
    Li J; Zhang DY; Wu XM
    Yao Xue Xue Bao; 2009 Dec; 44(12):1313-9. PubMed ID: 21351462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramolecular Aminoboration of Unfunctionalized Olefins.
    Yang CH; Zhang YS; Fan WW; Liu GQ; Li YM
    Angew Chem Int Ed Engl; 2015 Oct; 54(43):12636-9. PubMed ID: 26331979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 14. [Proteasome inhibitors].
    Saeki Y; Fukunaga K; Tanaka K
    Nihon Rinsho; 2010 Oct; 68(10):1818-22. PubMed ID: 20954323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.
    Fröhlich K; Holle JU; Aries PM; Gross WL; Moosig F
    Ann Rheum Dis; 2011 Jul; 70(7):1344-5. PubMed ID: 21173019
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    O'Connor OA; Wright J; Moskowitz C; Muzzy J; MacGregor-Cortelli B; Stubblefield M; Straus D; Portlock C; Hamlin P; Choi E; Dumetrescu O; Esseltine D; Trehu E; Adams J; Schenkein D; Zelenetz AD
    J Clin Oncol; 2005 Feb; 23(4):676-84. PubMed ID: 15613699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitor holds promise for patients with refractory multiple myeloma.
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):509-10. PubMed ID: 12113081
    [No Abstract]   [Full Text] [Related]  

  • 18. [Proteasome inhibitors for multiple myeloma].
    Yano H; Iida S
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():601-4. PubMed ID: 17476759
    [No Abstract]   [Full Text] [Related]  

  • 19. The persisting challenge of selective and specific proteasome inhibition.
    Groll M; Huber R; Moroder L
    J Pept Sci; 2009 Feb; 15(2):58-66. PubMed ID: 19109822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-Terminal peptidic boronic acids selectively inhibit human ClpXP.
    Knott K; Fishovitz J; Thorpe SB; Lee I; Santos WL
    Org Biomol Chem; 2010 Aug; 8(15):3451-6. PubMed ID: 20523950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.